GT 2016

Drug Profile

GT 2016

Latest Information Update: 22 Dec 2003

Price : $50

At a glance

  • Originator Gliatech (CEASED)
  • Developer Gliatech (CEASED); Nonindustrial source
  • Class Antihistamines; Neuroprotectants; Nootropics; Sleep disorder therapies; Small molecules
  • Mechanism of Action Histamine H3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Alzheimer's disease; Narcolepsy

Most Recent Events

  • 22 Dec 2003 Discontinued - Preclinical for Narcolepsy in USA (PO)
  • 22 Dec 2003 Discontinued - Preclinical for Alzheimer's disease in USA (PO)
  • 25 Aug 1998 No-Development-Reported for Alzheimer's disease in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top